ctrl+s GmbH | $1,083,350 | (Mar 7, 2025)
Medly AI | $2,194,785 | (Mar 7, 2025)
hema.to GmbH | $3,900,060 | (Mar 7, 2025)
Atalanta Therapeutics
- 29/01/2025
- Series B
- $75,000,000
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.
- Industry Biotechnology Research
- Website https://www.atalantatx.com/
- LinkedIn https://www.linkedin.com/company/atalanta-therapeutics/
Related People
Alicia SecorFounder
United States -
Greater Boston
Accomplished 25+ year healthcare executive with broad operational experience and a demonstrated track record in building and leading highly successful international cross-functional teams from product development through regulatory approval, commercialization and life-cycle management. Global general management and commercial experience across multiple therapeutic areas spanning orphan and prevalent diseases, injectable therapeutics, and surgical devices. Inspirational leader with significant experience in P&L management, M&A and business development, patient advocacy, capital raises and investor relations, corporate strategy and turnaround execution. Experienced public company CEO & board director.
Tiga AI | $2,000,000 | (Mar 7, 2025)
Lumata Health | $20,000,000 | (Mar 7, 2025)
CaPow | $15,000,000 | (Mar 7, 2025)
Uniti AI | $4,000,000 | (Mar 7, 2025)
WilsonAI | $1,700,000 | (Mar 7, 2025)
Epirus | $250,000,000 | (Mar 7, 2025)
Numeral(US) | $18,000,000 | (Mar 7, 2025)
Telescope(NORWAY) | $4,000,000 | (Mar 7, 2025)
TRIMTECH Therapeutics Limited | $31,000,000 | (Mar 7, 2025)
Intangible | $4,000,000 | (Mar 7, 2025)